Insider Selling: Medpace (NASDAQ:MEDP) President Sells 21,503 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) President Jesse Geiger sold 21,503 shares of the business’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total value of $12,808,476.98. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at $8,934,900. The trade was a 58.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Medpace Stock Down 0.5%

MEDP stock traded down $3.04 during midday trading on Friday, reaching $589.15. 235,536 shares of the company’s stock traded hands, compared to its average volume of 421,206. The company has a 50-day simple moving average of $525.46 and a two-hundred day simple moving average of $410.27. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $625.00. The company has a market cap of $16.60 billion, a price-to-earnings ratio of 41.20, a PEG ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business’s revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MEDP. Rothschild Redb lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Zacks Research upgraded shares of Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. Truist Financial set a $555.00 price target on shares of Medpace in a research note on Monday, October 27th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a research report on Wednesday, July 23rd. Finally, Robert W. Baird set a $613.00 price objective on Medpace in a report on Friday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $475.90.

Institutional Investors Weigh In On Medpace

Several institutional investors have recently modified their holdings of the business. Quent Capital LLC bought a new stake in shares of Medpace during the third quarter worth approximately $25,000. Geneos Wealth Management Inc. boosted its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Brooklyn Investment Group grew its holdings in Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after acquiring an additional 71 shares during the period. Whittier Trust Co. raised its position in shares of Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after acquiring an additional 35 shares during the last quarter. Finally, Employees Retirement System of Texas bought a new stake in shares of Medpace during the 2nd quarter valued at $36,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.